Program
Cannabidiol
Also written as “GWP42003-P”, “Cannabidiol Oral Solution” and “CBD”.
Its studies are mostly in Epilepsy · Lennox Gastaut Syndrome · Epilepsies, Myoclonic · Seizures · Spasms, Infantile, led by 16 companies.
Drug pageCannabidiol: every studyMany companies study it; this page follows only the 64 they lead. All 316 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticalsits history only | 315 open or running | phase 4since Oct 17, 2019 | Oct 7, 2010 | Aug 1, 2027phase 4 · NCT05044819 |
| INSYS Therapeuticsits history only | 50 open or running | phase 3since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Radius Pharmaceuticalsits history only | 50 open or running | phase 3since Jan 26, 2018 | Jul 22, 2016 | none ahead |
| Cardiol Therapeuticsits history only | 41 open or running | phase 3since Nov 2, 2020 | Nov 2, 2020 | none ahead |
| Pure Greenits history only | 40 open or running | phase 2since Sep 10, 2019 | Sep 10, 2019 | none ahead |
| Canopy Growthits history only | 30 open or running | phase 2since Aug 29, 2019 | Aug 29, 2019 | none ahead |
| Botanix Pharmaceuticalsits history only | 20 open or running | phase 2since Jun 19, 2018 | Jun 19, 2018 | none ahead |
| Stero Biotechsits history only | 20 open or running | phase 2since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Avecho Biotechnology | 11 open or running | phase 3since Apr 23, 2023 | Apr 23, 2023 | Sep 30, 2027phase 3 · NCT05840822 |
| Bod Australiaits history only | 10 open or running | phase 2since Dec 20, 2021 | Dec 20, 2021 | none ahead |
| dsm-firmenichits history only | 10 open or running | phase 1since Aug 20, 2024 | Aug 20, 2024 | none ahead |
| EmpowerPharmits history only | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
| Kalytera Therapeutics Israelits history only | 10 open or running | phase 2since Feb 10, 2019 | Feb 10, 2019 | none ahead |
| Laboratorio Elea Phoenixits history only | 11 open or running | phase 2since Sep 30, 2024 | Sep 30, 2024 | none ahead |
| Pure Green Pharmaceuticalsits history only | 10 open or running | phase 2since Mar 2, 2023 | Mar 2, 2023 | none ahead |
| Tiamat Australia Ptyits history only | 10 open or running | phase 1since Feb 14, 2025 | Feb 14, 2025 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Research UK and Benuvia Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Avecho Biotechnology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named cannabidiolINNProposed as its International Nonproprietary Name in WHO's List 115 · before, GWP42003-P, GWP42003
- Apr 23, 2023First study: phase 3 study in Sleep Initiation and Maintenance DisordersFirst studyNCT05840822 · 519 enrolled · Australia
Ahead
- Sep 30, 2027Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT05840822
TargetBeta
“Cannabinoid CB1 receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rimonabantrule | Sanofi | phase 3 | 39 |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 20 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
The one study Avecho Biotechnology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05840822Sleep Initiation and Maintenance Disorders · Australia | 3 | Active, not recruiting | Sep 30, 2027 | 519 |
How it is read
Names in the registry
- “GWP42003-P”, 17 entries
- “Cannabidiol Oral Solution”, 10 entries
- “Cannabidiol”, 7 entries
- “CBD”, 5 entries
- “GWP42003”, 4 entries
Codes read as this program: JZP926.
Conditions, from the studies’ own filings
- Epilepsy, 7 studies
- Lennox Gastaut Syndrome, 6 studies
- Epilepsies, Myoclonic, 5 studies
- Seizures, 4 studies
- Spasms, Infantile, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.